Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428190802353625 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Complex Genetic Evolution and Treatment Challenges in Myeloid Neoplasms: A Case of Persistent t(2;3)(p15~23;q26)/ Rearrangement, Mutation, and Transient Chimera.
Cancer Genomics Proteomics
December 2024
Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway;
Background/aim: Myelodysplastic syndromes (MDSs) are clonal bone marrow disorders characterized by ineffective hematopoiesis. They are classified based on morphology and genetic alterations, with SF3B1 variants linked to favorable prognosis and MECOM rearrangements associated with poor outcomes. The combined effects of these alterations remain unclear.
View Article and Find Full Text PDFSynergistic effects of AgNPs and zileuton on PCOS via ferroptosis and inflammation mitigation.
Redox Rep
December 2025
Department of Medical Biochemistry, Tanta Faculty of Medicine, Tanta University, Tanta, Egypt.
Background: The most prevalent endocrine disorder affecting women is PCOS. Programmed death of ovarian cells has yet to be elucidated. Ferroptosis is a kind of iron-dependent necrosis featured by significantly Fe-dependent lipid peroxidation.
View Article and Find Full Text PDFArginine supplementation improves lactate dehydrogenase levels in steady-state sickle cell patients: preliminary findings from Kinshasa, the Democratic Republic of Congo.
Front Pain Res (Lausanne)
November 2024
Département de Pédiatrie, Cliniques Universitaires de Kinshasa, Faculté de Médecine, Université de Kinshasa (UNIKIN), Kinshasa, The Democratic Republic of Congo.
Background: Sickle cell disease (SCD) disrupts oxygen transport due to the abnormal shape and rigidity of red blood cells, leading to hemolysis. Hemolysis, a major co-morbidity in SCD, is indicated by elevated levels of lactate dehydrogenase (LDH). Arginine depletion, which is essential for nitric oxide (NO) synthesis, contributes to various complications in SCD.
View Article and Find Full Text PDFPractical guide for disease-modifying medication management of children and adolescents with sickle cell disease.
Hematology Am Soc Hematol Educ Program
December 2024
Department of Pediatrics, The Research Institute at Nationwide Children's Hospital, Columbus, OH.
Hydroxyurea has historically been the sole disease-modifying medication (DMM) for sickle cell disease (SCD). However, 3 newer DMMs, L-glutamine, voxelotor, and crizanlizumab, were approved for children and adolescents with SCD since 2017. Despite their emergence, treatment barriers, including access, affordability, and nonadherence, limit the optimization of DMMs in the clinical setting.
View Article and Find Full Text PDFTransfusions, disease-modifying treatments, and curative therapies for sickle cell anemia in Africa: where are we now?
Hematology Am Soc Hematol Educ Program
December 2024
Department of Haematology, University of Benin Teaching Hospital, Benin City, Nigeria.
The mortality burden of sickle cell anemia (SCA) is centered in sub-Saharan Africa. In addition to a lack of systematic programs for early diagnosis, access to disease-modifying treatments is limited to only a few urban centers. Providing a safe and adequate blood supply is a major challenge, heightening mortality from SCA-associated complications that require urgent blood transfusion and making the delivery of regular transfusion therapy for stroke prevention nonfeasible.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!